Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jun 24, 2022 4:47pm
193 Views
Post# 34781399

RE:RE:RE:RE:Enough on Trogarzo/Rukobia - Back to what matters - TH-1902

RE:RE:RE:RE:Enough on Trogarzo/Rukobia - Back to what matters - TH-1902

I know you're an angry skeptic Momo, but your characterization is wrong.  He has stated the various facts the company has mentioned (1b start date, some patients rolling in from 1a, etc...).  Those are all statements of fact from management, not guessing.  He has other info he has gleaned and he is trying to put together a scenario analysis for an investor to think about.  Scenarios are speculative, but one of the various paths laid out will occur since he speculates from no efficacy all the way to ,ultiple tumor efficacies.  


So to correct your statement -  there is a source (management and his other sources), the info is either factual or based on comps who've trodden the same path, he's definitely interpolating the holes in the data based on that (of course any investment in an unknown outcome involves speculation or you should just buy bonds with known incomes),  it's pretty balanced between failure and success.  Of course, any investor hopes for success but is clear-eyed enough to know risks go both ways.  At least try to be analytical, move the analysis forward either bullish or bearish but with facts and good thoughtful conclusions, instead of just snarky pablum.


Momo25 wrote: He has no source, nor viable information. Just iterative speculation. I am suspecting, he runs a biotech fund and tries to keep TH shareholders as much optimistic as he could. That's it, that's all.

 

<< Previous
Bullboard Posts
Next >>